ORPHA:300324
Persistent polyclonal B-cell lymphocytosis
Also known as: PPBL · Persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes
Publications
100
43.8th percentile
Trials
0
Interventional, condition-specific
Researchers
548
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare, generally benign, lymphoproliferative hematological disease characterized by: chronic, stable, persistent, polyclonal lymphocytosis of memory B-cell origin, the presence of binucleated lymphocytes in the peripheral blood, and a polyclonal increase in serum immunoglobulin M (IgM). Patients are most frequently asymptomatic or may present with mild .
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011672
- MeSH:C564707
- OMIM:606445
- UMLS:C1847973
Additional Mondo synonyms (2)
persistent polyclonal B-cell lymphocytosis · persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
100 matched papers (30 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
100
100 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
100 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
30 in the last 10 years · medium confidence · 43.8th percentile (publications denominator)
Phrase hits: 100 · MeSH hits: 0
Who's working on it?
548
Distinct author names in 100 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Troussard X11 papers · 2021
Laboratoire d'Hématologie Côte de Nacre, Université Caen Basse Normandie Caen, Registre Régional des Hémopathies Malignes de Basse Normandie, France.
Papers in Europe PMC - 02Mossafa H10 papers · 2014
Département de génétique humaine, Laboratoire Pasteur-Cerba, Cergy-Pontoise, France.
Papers in Europe PMC - 03Lesesve JF9 papers · 2021
Service d'Hématologie Biologique, CHU Brabois , Nancy , France.
Papers in Europe PMC - 04Delage R7 papers · 2014
Centre d'Hématologie et d'Immunologie Clinique, Hôpital du St-Sacrement, Laval University, Quebec, Ste-Foy, Canada.
Papers in Europe PMC - 05Darveau A6 papers · 2014
Département de Biochimie, de Microbiologie et de Bio-Informatique, Pavillon Alexandre-Vachon, 1045 avenue de la Médecine, Bureau 3428, Université Laval, Québec, QC, Canada G1V 0A6.
Papers in Europe PMC - 06Cornet E5 papers · 2014
Laboratoire d'hématologie, CHU Côte de Nacre, Caen, France.
Papers in Europe PMC - 07Huemer HP4 papers · 2005Papers in Europe PMC
- 08Larcher C4 papers · 2005
Institute for Hygiene, University of Innsbruck, Austria.
Papers in Europe PMC - 09Mitterer M4 papers · 2005
Department of Haematology, General Hospital, Bozen, Italy.
Papers in Europe PMC - 10Callet-Bauchu E3 papers · 2017
Laboratoire Central d'Hématologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Persistent polyclonal B-cell lymphocytosis" OR "Persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes"
MeSH descriptor terms unioned into the query: Persistent Polyclonal B-Cell Lymphocytosis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Persistent polyclonal B-cell lymphocytosis" OR "Persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PPBL
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:39:25.307Z